Tandem Diabetes Care (NASDAQ:TNDM) traded higher on Tuesday after Citi upgraded the insulin pump maker to Neutral from Sell, citing a shift in its risk-reward setup following the company’s ...
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” fourth-quarter 2025 investor letter. A ...
Tandem Diabetes Care's top-line growth hasn't been great over the past few years. If it can successfully address challenges detrimental to revenue growth, it may become an attractive stock -- even ...
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2025 results after the financial markets close on Thursday, ...
“Ease of use is what drives adoption,” CEO John Sheridan explains to Bloomberg Intelligence about what can drive further insulin pump penetration. In this episode of Vanguards of Health Care, Sheridan ...
Tandem Diabetes Care, Inc. TNDM is driving transformative innovation to help reduce the burden and create new possibilities for people living with diabetes. Its strong focus on overseas expansion is ...